Other viral bioweapons: Ebola and Marburg hemorrhagic fever

Dermatologic Clinics

Volumn 22, Issue 3, 2004, Pages 291-302

  Salvaggio, Michelle R ^a   Baddley, John W ^a,b,c  

^a University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEAZAARISTEROMYCIN; ADENOSYLHOMOCYSTEINASE INHIBITOR; VIRUS VACCINE;

ABDOMINAL PAIN; AEROSOL; AFRICA; AIRBORNE INFECTION; ARTHRALGIA; ASTHENIA; BACKACHE; BIOLOGICAL WARFARE; BLEEDING TENDENCY; BLOOD VESSEL PERMEABILITY; BREAST FEEDING; CELL CULTURE; DEMOCRATIC REPUBLIC CONGO; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG SAFETY; EBOLA VIRUS; GENE SEQUENCE; HEADACHE; HEALTH CARE PERSONNEL; HUMAN; INFECTION CONTROL; INFLUENZA; INOCULATION; MALAISE; MARBURG VIRUS; MORBIDITY; MORTALITY; MYALGIA; NAUSEA AND VOMITING; NONHUMAN; PHLEBOTOMY; PRIORITY JOURNAL; REVIEW; SEXUAL TRANSMISSION; SKIN BIOPSY; SUDAN; THORAX PAIN; VIRUS GENE; VIRUS GENOME; VIRUS HEMORRHAGIC FEVER; VIRUS HEPATITIS; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS VIRULENCE;

BIOLOGICAL WARFARE; BIOTERRORISM; EBOLAVIRUS; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; MALE; MARBURG VIRUS DISEASE; PROGNOSIS; RISK ASSESSMENT; RNA VIRUSES; SURVIVAL RATE; UNITED STATES;

EID: 2942637320     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2004.03.003     Document Type: Review

References (86)

1. Infectious Diseases Society of America Bioterrorism information and resources. Viral hemorrhagic fever. Updated September 10, 2003. Available at: http://idsociety.org/bt/biotemplate. Accessed October 3, 20003
2. Khan A., Levitt A., Sage M. Biological and chemical terrorism: strategic plan for preparedness and response. MMWR. 49(RR-4):2000;1-14
3. Borio L., Inglesby T., Peters C.J., Schmaljohn A.L., Hughes J.M., Jarhling P.B., et al. Hemorrhagic fever viruses as biological weapons. JAMA. 287(18):2002;2391-2405
4. Davis C.J. Nuclear blindness: an overview of the biological weapons programs of the former Soviet Union and Iraq. Emerg Infect Dis. 5(4):1999;509-512
5. Bausch D.G., Ksiazek T.G. Viral hemorrhagic fevers including hantavirus pulmonary syndrome in the Americas. Clin Lab Med. 22:2002;981-1020
6. Miller J., Engelberg S., Broad W. Germs: biological weapons and America's secret war. 2001;Simon & Schuster, New York
7. Deitrich M. Marburg virus disease. Pattyn S.R. Ebola virus haemorrhagic fever. 1978;182-186 Elsevier/North Holland, Amsterdam
8. Slenczka W.G. The Marburg virus outbreak of 1967 and subsequent episodes. Curr Top Microbiol Immunol. 235:1999;49-75
9. Sanchez A., Khan A.S., Zaki S.R., Nabel G.J., Ksiasek T.G., Peters C.J. Filoviridae: Marburg and Ebola viruses. Knipe D.M., Howley P.M. Field's virology. 4th edition:2001;1279-1304 Lippincott, Williams and Wilkins, Philadelphia
10. Johnson K.M., Webb P.A., Lange J.V., Murphy F.A. Isolation and characterization of a new virus causing acute haemorrhagic fever in Zaire. Lancet. 1:1977;569-571
11. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ. 56:1978;271-293
12. Ebola haemorrhagic fever in Sudan, 1976. Bull World Health Organ. 56:1978;247-270
13. Cox N.J., McCormick J.B., Johnson J.M., Kiley M.P. Evidence for two subtypes of Ebola virus based on oligonucleotide mapping of RNA. J Infect Dis. 147:1983;272-275
14. Sanchez A., Trappier S.G., Mahy B.W.J., Peters C.J., Nichol S.T. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci USA. 93:1996;3602-3607
15. Ebola virus infection in imported primates - Virginia, 1989. MMWR. 38(48):1989;831-832
16. Update. Filovirus infection associated with contact with nonhuman primates or their tissues. MMWR. 39(24):1990;404-405
17. Jarhling P.B., Geisbert T.W., Dalgard D.W., Johnson E.D., Ksiazek T.G., Hall W.C., et al. Preliminary report: isolation of Ebola virus from monkeys imported to USA. Lancet. 335:1990;502-505
18. Le Guenno B., Formentry P., Wyers M., Gounon P., Walker F., Boesch C. Isolation and partial characterization of a new strain of Ebola virus. Lancet. 345(8960):1995;1271-1274
19. Formenty P., Hatz C., Le Guenno B., Stoll A., Rogenmoser P., Widmer A. Human infection due to Ebola virus, subtype Côted'Ivoire: clinical and biologic presentation. J Infect Dis. 179(Suppl 1):1999;S48-S53
20. Feldmann H., Kiley M.P. Classification, structure and replication of filoviruses. Curr Top Microbiol Immunol. 235:1999;1-21
21. Geisbert T.W., Jarhling P.B. Differentiation of filoviruses by electron microscopy. Virus Res. 39:1995;129-150
22. Sanchez A., Kiley M.P., Holloway B.P., Auperin D.D. Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res. 29:1993;215-240
23. Bukreyev A.A., Volchkov V.E., Blinov V.M., Dryga S.A., Netesov S.V. The complete nucleotide sequence of the Popp (1967) strain of Marburg virus: a comparison with the Musoke (1980) strain. Arch Virol. 140:1999;1589-1600
24. Kiley M.P., Cox N.J., Elliot L.H., Sanchez A., DeFries R., Buchmeier M.J., et al. Physiochemical properties of Marburg virus: evidence for three distinct virus strains and their relationship to Ebola virus. J Gen Virol. 69:1988;1957-1967
25. Elliott L.H., Kiley M.P., McCormick J.B. Descriptive analysis of Ebola virus proteins. Virol. 147:1985;169-176
26. Basler C.F., Wang X., Mühlberger E., Volchkov V., Paragas J., Klenk H.-D. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci USA. 97(22):2000;12289-12294
27. Takada A., Robison C., Goto H., Sanchez A., Murti K.G., Whitt M.A., et al. A system for functional analysis of Ebola virus glycoprotein. Proc Natl Acad Sci USA. 94:1997;14764-14769
28. Ito H., Watanabe S., Sanchez A., Whitt M., Kawaoka Y. Mutational analysis of the putative fusion domain of Ebola virus glycoprotein. J Virol. 73(10):1999;8907-8912
29. Yang Z.-Y., Delgado R., Xu L., Todd R.F., Nabel E.G., Sanchez A., et al. Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science. 279:1998;1034-1037
30. Yang Z.-Y., Duckers H.J., Sullivan N.J., Sanchez A., Nabel E.G., Nabel G.J. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell toxicity and injury. Nat Med. 6(8):2000;886-889
31. Sanchez A., Yang Z.-Y., Xu L., Nabel G.J., Crews T., Peters C.J. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J Virol. 72(8):1998;6442-6447
32. Dowell S.F., Mukunu R., Ksiazek T.G., Khan A.S., Rollin P.E., Peters C.J. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis. 179(Suppl 1):1999;S87-S91
33. Francesconi P., Yoti Z., Declich S., Onek P.A., Fabiani M., Olango J., et al. Ebola hemorrhagic fever transmission and risk factors of contacts, Uganda. Emerg Infect Dis. 9(11):2003;1430-1437
34. Zaki S.R., Shieh W.-J., Greer P.W., Goldsmith C.S., Ferebee T., Katshitshi J., et al. A novel immunohistochemical assay for the detection of Ebola virus in the skin: implications for diagnosis, spread and surveillance of Ebola hemorrhagic fever. J Infect Dis. 179(Suppl 1):1999;S36-S47
35. Emond R.T.D., Evans B., Bowen E.T.W., Lloyd G. A case of Ebola infection. BMJ. 2:1977;541-544
36. Rowe A.K., Bertolli J., Kahn A.S., Mukunu R., Muyembe-Tamfum J.J., Bressler D., et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. J Infect Dis. 179(Suppl 1):1999;S28-S35
37. Rodriguez L.L., De Roo A., Guimard Y., Trappier S.G., Sanchez A., Bressler D., et al. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J Iinfect Dis. 179(Suppl 1):1999;S170-S176
38. Borchert M., Muyembe-Tamfum J.J., Colebunder R., Libande M., Sabue M., Van der Stuyft P. A cluster of Marburg virus disease involving an infant. Trop Med Int Health. 7(10):2002;902-906
39. Feldmann H., Czub M., Jones S., Dick D., Garbutt M., Grolla A., et al. Emerging and re-emerging infectious diseases. Med Microbiol Immunol. 191:2002;63-74
40. Jaax N., Jarhling P., Geisbert T., Geisbert J., Steele K., McKee K. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet. 346:1995;1669-1671
41. Update. Outbreak of Ebola viral hemorrhagic fever - Zaire, 1995. MMWR. 44:1995;468-469
42. Khan A.S., Tshioki F.K., Heymann D.L., Le Guenno B., Nabeth P., Kerstiëns B., et al. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. J Iinfect Dis. 179(Suppl 1):1999;S76-S86
43. Hospital Infection Control Practices Advisory Committee Recommendations for isolation precautions in hospitals. Updated February 18, 1997. Available at http://www.cdc.gov/ncidod/hip/isolat/isopart2.htm. Accessed September 23, 2003
44. Richards G.A., Murphy S., Jobson R., Mer M., Zinman C., Taylor R., et al. Unexpected Ebola virus in a tertiary care setting: clinical and epidemiologic aspects. Crit Care Med. 28(1):2000;240-244
45. Outbreak of Ebola hemorrhagic fever - Uganda, August 2000-January 2001. MMWR. 50:2001;73-76
46. World Health Organization Ebola hemorrhagic fever in the Republic of the Congo - Update 12. May 7, 2003. Available at: http://www/who.int/csr/don/ 2003_05_07/en/print.html. Accessed October 3, 2003
47. Leirs J., Mills J.N., Krebs J.W., Childs J.E., Akaibe D., Woollen N., et al. Search for the Ebola virus reservoir in Kikwit, Democratic Republic of the Congo: reflections on a vertebrate collection. J Infect Dis. 179(suppl 1):1999;S155-S163
48. Swanepoel R., Leman P.A., Burt F.J., Zachariades N.A., Braack L.E.O., Ksiazek T.G., et al. Experimental inoculation of plants and animals with Ebola virus. Emerg Infect Dis. 2:1996;321-325
49. Enria D.A., Pinheiro F. Rodent-borne emerging viral zoonosis. Infect Dis Clin North Am. 14(1):2000;167-183
50. Fisher-Hoch S.P., Brammer T.L., Trappier S.G., Hutwagner L.C., Farrar B.B., Ruo S.L., et al. Pathogenic potential of filoviruses: role of geographic origin of primate host and virus strain. J Infect Dis. 166:1992;753-763
51. Rollin P.E., Williams R.J., Bressler D.S., Pearson S., Cottingham M., Pucak G., et al. Ebola (Subtype Reston) virus among quarantined nonhuman primates recently imported from the Philippines to the United States. J Infect Dis. 179(suppl 1):1999;S108-S114
52. Peters C.J., LeDuc J.W. An introduction to Ebola: the virus and the disease. J Infect Dis. 179(suppl 1):1999;ix-xvi
53. Peterson A.T., Bauer J.T., Mills J.N. Ecologic and geographic distribution of filovirus disease. Emerg Infect Dis. 10(1):2004;. Available at: http://www.cdc.gov/ncidod/EID/vol10no1/03-0125.htm. Accessed December 5, 2003
54. Bwaka M.A., Bonnet M.-J., Calain P., Colebunders R., De Roo A., Guimard Y., et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis. 179(suppl 1):1999;S1-S7
55. Peters C.J., Kahn A.S. Filovirus diseases. Curr Top Microbiol Immunol. 235:1999;85-95
56. Leroy E.M., Baize S., Volchkov V.E., Fisher-Hoch S.P., Georges-Courbot M.-C., Lansoud-Soukate J. Human asymptomatic Ebola infection and strong inflammatory response. Lancet. 355:2000;2210-2215
57. Gear J.S.S., Cassel G.A., Gear A.J., Trappler B., Clausen L., Meyers A.M., et al. Outbreak of Marburg virus disease in Johannesburg. BMJ. 4:1975;489-493
58. Smith D.H., Isaacson M., Johnson K.M., Bagshawe A., Johnson B.K., Swanepoel R., et al. Marburg-virus disease in Kenya. Lancet. 1:1982;816-820
59. Bonnet M.-J., Akamituna P., Mazaya A. Epidemic in Kikwit, Democratic Republic of the Congo. Emerg Infect Dis. 4(3):1998;508-510
60. Ryabchikova E.I., Kolesnikova L.V., Luchko S.V. An analysis of pathogenesis of two animal models of Ebola virus infection. J Infect Dis. 179(suppl 1):1999;S199-S202
61. Update. Management of patients with suspected viral hemorrhagic fever - United States. MMWR. 44(25):1995;475-479
62. Epidemiologic notes and reports update: Ebola-related filovirus infection in nonhuman primates and interim guidelines for handling nonhuman primates during transit and quarantine. MMWR. 39(2):1990;22-24
63. Update. Filovirus infections among persons with occupational exposure to nonhuman primates. MMWR. 39(16):1990;266
64. Formenty P., Boesch C., Wyers M., Steiner C., Donati F., Dind F., et al. Ebola virus outbreak among wild chimpanzees living in a rain forest of Côte d'Ivoire. J Infect Dis. 179(suppl 1):1999;S120-S126
65. World Health Organization Marburg fever, Democratic Republic of the Congo. May 14. WHO. 74:1999;145
66. Bausch D.G., Borchert M., Grein T., Roth C., Swanepeol R., Libande M.L., et al. Risk factors for Marburg Hemorrhagic Fever, Democratic Republic of the Congo. Emerg Infect Dis. 9(12):2003;. Available at: http://www.cdc.gov/ncidod/ EID/vol9no12/03-0355.htm. Accessed December 5, 2003
67. Zaki S.R., Goldsmith C.S. Pathologic features of filovirus infections in humans. Curr Top Microbiol Immunol. 235:1999;97-116
68. Feldmann H., Bugany H., Mahner F., Klenk H.-D., Drenckhahn D., Schnittler H.-J. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J Virol. 70(4):1996;2208-2214
69. Harcourt B.H., Sanchez A., Offermann M.K. Ebola virus selectively inhibits responses to interferons, but not to interleukin-1β, in endothelial cells. J Virol. 73(4):1999;3491-3496
70. Geisbert T.W., Young H.A., Jarhling P.B., Davis K.J., Kagan E., Hensley L.E. Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis. 188:2003;1618-1629
71. Bosio C.M., Aman J., Grogan C., Hogan R., Ruthel G., Negley D., et al. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis. 188:2003;1630-1638
72. Schnittler H.-J., Feldmann H. Marburg and Ebola hemorrhagic fevers: does the primary course of infection depend on the accessibility of organ-specific macrophages? Clin Infect Dis. 27:1998;404-406
73. Villinger F., Rollin P.E., Brar S.S., Chikkala N.F., Winter J., Sundstrom J.B., et al. Markedly elevated levels of interferon (IFN)-γ, IFN-α, Interleukin (IL)-2, IL-10, and tumor necrosis factor-α associated with fatal Ebola virus infection. J Infect Dis. 179(suppl 1):1999;188-191
74. Baize S., Leroy E.M., Georges-Courbot M.-C., Capron M., Lansoud-Soukate J., Debre P., et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med. 5(4):1999;423-426
75. Baize S., Leroy E.M., Georges A.J., Georges-Courbot M.-C., Capron M., Bedjabaga I. Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol. 128:2002;163-168
76. Centers for Disease Control BMBL Section III. Laboratory Biosafety Level Criteria. Updated November 30, 2000. Available at: http://www.cdc.gov/od/ohs/ biosfty/bmbl4/bmbl4s3.htm. Accessed October 1, 2003
77. Centers for Disease Control BMBL Appendix A. Primary containment: biological safety cabinets. Updated June 17, 1999. Available at: http://www.cdc.gov/od/ohs/biosfty/bmbl4/b4aa.htm. Accessed October 1, 2003
78. Bowen E.T.W., Lloyd G., Harris W.J., Platt G.S., Baskerville A., Vella E.E. Viral haemorrhagic fever in southern Sudan and northern Zaire. Lancet. 1:1977;571-573
79. Pattyn S., Van der Groen G., Jacob W., Piot P., Courteille G. Isolation of Marburg-like virus from a case of haemorrhagic fever in Zaire. Lancet. 1:1977;573-574
80. Ksiasek T.G., Rollin P.E., Jarhling P.B., Johnson E., Dalgard D.W., Peters C.J. Enzyme immunosorbent assay for Ebola virus antigens in tissues of infected primates. J Clin Microbiol. 30(4):1992;947-950
81. Ksiazek T.G., West C.P., Rollin P.E., Jarhling P.B., Peters C.J. ELISA for the detection of antibodies to Ebola viruses. J Infect Dis. 179(suppl 1):1999;S192-S198
82. Jarhling P.B., Geisbert T.W., Geisbert J.B., Swearengen J.R., Bray M., Jaax N.K., et al. Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infection. J Infect Dis. 179(suppl 1):1999;S224-S234
83. Mupapa K., Massamb M., Kibadi K., Kuvula K., Bwaka A., Kipasa M., et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis. 179(Suppl 1):1999;S18-S23
84. Huggins J., Zhang Z.-X., Bray M. Antiviral therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model. J Infect Dis. 179(Suppl 1):1999;S240-S247
85. Sullivan N.J., Geisbert T.W., Geisbert J.B., Xu L., Yang Z.-Y., Roedere M., et al. Accelerated vaccination for Ebola hemorrhagic fever in non-human primates. Nature. 424:2003;681-684
86. ScienceDaily NIAID vaccine enters human trial. November 19, 2003. Available at: http://www.sciencedaily.com/releases/2003/11/031119075818.htm. Accessed December 1, 2003